Clinical trials: Risk of Venous Thrombosis, open to volunteers
Portal Vein Thrombosis, Anticoagulant Therapy
Direct Oral Novel Anticoagulants for Patients With High-risk Gastroesophageal Variceal Bleeding and Portal Vein Thrombosis
This study aims to explore the safety and efficacy of oral administration of a novel anticoagulant (rivaroxaban) in patients with cirrhosis accompanied by high-risk esophagogastric variceal bleeding and portal vein thrombosis…
- Conditions
- Portal Vein Thrombosis, Anticoagulant Therapy, Variceal Bleeding
- Trial name
- NCT07602062
- Testing
- Rivaroxaban
- Where
- China
- Volunteers
- 175 people
- Sponsor
- Shanghai Zhongshan Hospital
Acute Leukemia, Newly Diagnosed Acute Leukemia
Real World Assessment of Venous Thromboembolic Risk in Hospitalized Patients With Acute Leukemia
This is a observational study designed to identify risk factors for venous thromboembolism in patients with newly diagnosed acute leukemia at the time of first admission to a Hematology Ward.
- Conditions
- Acute Leukemia, Newly Diagnosed Acute Leukemia, Thromboprophylaxis, Thromboprophylaxis in Acute Leukemia
- Trial name
- ReVeAL (NCT07831668)
- Volunteers
- 250 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Cerebral Venous Sinus Thrombosis
MENA Regional Endovascular Intervention for Venous Cerebral Venous Sinus Thrombosis
REVIVE-CVST is a multicenter, prospective, randomized, open-label, blinded-endpoint (PROBE) trial evaluating whether early endovascular thrombectomy (EVT) combined with standard anticoagulation improves outcomes compared to…
- Trial name
- REVIVE-CVST (NCT07548346)
- Testing
- Endovascular Thrombectomy, Anticoagulation Therapy
- Where
- 14 sites in Egypt, Jordan and 6 more
- Volunteers
- 440 people
- Sponsor
- Middle East North Africa Stroke and Interventional Neurotherapies Organization
Venous Thromboembolism, Bleeding
Avoiding Risks of Thrombosis and Bleeding in Surgery (ARTS) Trial
Avoiding Risks of Thrombosis and bleeding in Surgery (ARTS) trial is a pragmatic, international, multicenter, randomized controlled open label trial comparing a direct oral anticoagulant (DOAC) - oral factor Xa inhibitor apixaban…
- Trial name
- ARTS (NCT06523959)
- Testing
- Apixaban 2.5 MG
- Where
- Finland
- Volunteers
- 5,436 people
- Sponsor
- Clinical Urology and Epidemiology Working Group
Venous Thromboembolism (VTE), Cancer
Vortosiran for VTE Prevention
Blood clots remain a serious cause of illness and death. Long-term treatment and prevention of these clots with blood thinners is often limited by bleeding risk, drug interactions, and daily dosing, leading many patients to stop…
- Conditions
- Venous Thromboembolism (VTE), Cancer, Pulmonary Embolism (Diagnosis)
- Trial name
- NCT07850453
- Testing
- Vortosiran
- Where
- 30 sites in Bulgaria, France and 2 more
- Volunteers
- 150 people
- Sponsor
- Ribocure Pharmaceuticals AB
Thromboembolic Disease
The Correlation of Lewis Antigens With VTE
The goal of this observational study is to learn if certain factors in a person's blood are linked to a history of venous thromboembolic disease (VTED), which includes conditions like deep vein thrombosis.
- Trial name
- NCT07402005
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Larissa University Hospital
Venous Thromboembolism (VTE), Acute Myocardial Infarction With ST Segment Elevation
Heat Shock Protein 47 in Thrombosis
The goal of this observational study is to learn if the novel biomarker Heat shock protein 47 (HSP47) can be used as a prognostic marker for vascular disease in people with acute venous thromboembolism (VTE), myocardial…
- Conditions
- Venous Thromboembolism (VTE), Acute Myocardial Infarction With ST Segment Elevation, Stroke (in Patients With Atrial Fibrillation)
- Trial name
- NCT06731673
- Where
- 2 sites in Denmark, Germany
- Volunteers
- 340 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Cancer-associated Thrombosis
Development of a Risk Stratification Score for Recurrent Venous Thromboembolism and Treatment-related Clinically Relevant Bleeding in Patients With Cancer-associated Thrombosis
The objective of this study is to prospectively develop a risk assessment model (RAM) that accurately identifies anticoagulated cancer-associated thrombosis (CAT) patients at low- and high-risk of recurrent venous thromboembolism…
- Trial name
- CAN-CATCH (NCT06894576)
- Where
- Canada
- Volunteers
- 1,000 people
- Sponsor
- Ottawa Hospital Research Institute
Postthrombotic Syndrome
DVT Burden and the Risk of Post-thrombotic Syndrome
Post-thrombotic syndrome (PTS) is the most common chronic complication of deep vein thrombosis (DVT), with major consequences for patient quality of life and cost of management.
- Trial name
- DVT-Burden (NCT06385353)
- Testing
- Quantification of deep vein thrombosis burden and assessment of post-thrombotic syndrome
- Where
- 27 sites in France
- Volunteers
- 400 people
- Sponsor
- Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Venous Thromboembolism (VTE), NSCLC (Advanced Non-small Cell Lung Cancer)
Effects of Genomic Profiles on Thromboembolic Risk in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer
Multicenter, prospective observational study (15 Oncologic Centers, in Italy). The purpose of the study is to assess the thromboembolic potential in patients with oncogene-addicted and wild-type NSCLC.
- Trial name
- NCT07288632
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- University Of Perugia
Polycythemia Vera, Essential Thrombocythemia
AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms
Philadelphia-negative myeloproliferative neoplasms (MPN) are frequent and chronic myeloid malignancies including Polycythemia Vera (PV), essential thrombocythemia (ET), Primary Myelofibrosis (PMF) and Prefibrotic myelofibrosis…
- Conditions
- Polycythemia Vera, Essential Thrombocythemia, Prefibrotic/Early Primary Myelofibrosis, JAK2 V617F
- Trial name
- AVAJAK (NCT05198960)
- Testing
- Direct Oral Anticoagulants, Low-dose aspirin
- Where
- 42 sites in France
- Volunteers
- 1,308 people
- Sponsor
- University Hospital, Brest
Lung Cancer, Venous Thromboembolism
Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors
The purpose of this observational study is to explore the incidence, risk factors, and relationship with therapeutic outcomes of VTE (venous thromboembolism) and ATE (arterial thromboembolism) associated with immune checkpoint…
- Conditions
- Lung Cancer, Venous Thromboembolism, Arterial Thromboembolism, Immune Checkpoint Inhibitors (ICIs)
- Trial name
- NCT06950697
- Where
- 5 sites in China
- Volunteers
- 2,400 people
- Sponsor
- Beijing Chao Yang Hospital
Pulmonary Embolism (Diagnosis), Venous Thromboembolism (VTE)
3D-EIT for Diagnosis and Monitoring of Pulmonary Embolism
This prospective observational study aims to validate three-dimensional electrical impedance tomography (3D-EIT) as a non-invasive bedside tool for the diagnosis and longitudinal monitoring of pulmonary embolism (PE).
- Trial name
- TIDE-PE (NCT07560293)
- Volunteers
- 115 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital
Lung Cancer (Diagnosis), Deep Vein Thrombosis (DVT)
Study of Risk Factors and Prediction of Blood Clots After Lung Cancer Surgery
The goal of this observational study is to learn about the risk factors and prediction of postoperative venous thromboembolism (VTE) in patients undergoing lung cancer surgery.
- Conditions
- Lung Cancer (Diagnosis), Deep Vein Thrombosis (DVT), Venous Thromboembolism (VTE)
- Trial name
- NCT07439991
- Testing
- Prospective Perioperative Data Collection
- Where
- China
- Volunteers
- 900 people
- Sponsor
- The First Hospital of Jilin University
Venous Thromboembolism (VTE), Post Partum Women
Prevention of Postpartum Venous Thromboembolism in Women at Intermediate Risk
Venous thromboembolism (VTE) is currently the second cause of death in women of reproductive age worldwide. The incidence of VTE during pregnancy is 1.2 to 1.4/1000 women, half of VTE occurring during postpartum and as PE in…
- Trial name
- MUM-VTE (NCT06845423)
- Testing
- Low molecular weight heparin
- Where
- 18 sites in France
- Volunteers
- 2,400 people
- Sponsor
- University Hospital, Brest
Pulmonary Embolism, Venous Thromboembolism
STRATEGY-PE: Real-World Treatment Strategies for Intermediate-High Risk Pulmonary Embolism
This study aims to compare the effectiveness and safety of three treatment strategies (Anticoagulation, Thrombolysis, and Mechanical Thrombectomy) for patients with intermediate-high risk acute pulmonary embolism (PE) in a…
- Trial name
- STRATEGY-PE (NCT07603700)
- Testing
- Anticoagulants, Thrombolytic Agents, Mechanical Thrombectomy Devices
- Where
- China
- Volunteers
- 1,300 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
DVT of Legs
Deep Venous Thrombosis and Long Term Complications
In this cohort study, the investigators will investigate the concentration of biomarkers, e.g., inflammatory, anti-inflammatory, immunological, senescent, biochemical ratio-calculations, blood cell type, and and long term…
- Trial name
- NCT05789108
- Testing
- Blood sample and Ultrasound examination
- Where
- Denmark
- Volunteers
- 178 people
- Sponsor
- Ove Andersen
Interstitial Lung Disease, Venous Thromboembolism
Risk Factors of Venous Thrombotic Event in Interstitial Lung Disease
This study aims to determine the incidence of venous thromboembolic events (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), among hospitalized patients with interstitial lung disease (ILD).
- Conditions
- Interstitial Lung Disease, Venous Thromboembolism, Pulmonary Embolism, Deep Venous Thrombosis
- Trial name
- NCT07833254
- Volunteers
- 100 people
- Sponsor
- Sohag University
Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT)
VTEval Project - Prospective Cohort Studies to Evaluate and Improve Diagnostics, Management Strategies and Risk Stratification in VTE
Venous thromboembolism (VTE) with its two clinical manifestations deep vein thrombosis (DVT) and pulmonary embolism (PE) is a life-threatening disease that is associated with considerable morbidity and mortality.
- Conditions
- Venous Thromboembolism (VTE), Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE)
- Trial name
- VTEval (NCT02156401)
- Where
- Germany
- Volunteers
- 2,000 people
- Sponsor
- Johannes Gutenberg University Mainz
Diabete Mellitus, Retina Vein Occlusion
Serum Cholinesterases, Paraoxonase, and Cardiovascular Risk After Intravitreal Bevacizumab
Bevacizumab, an anti-VEGF (vascular endothelial growth factor) agent used in the treatment of diabetic retinopathy and macular edema associated with retinal vein occlusion, is commonly administered in ophthalmology clinics…
- Conditions
- Diabete Mellitus, Retina Vein Occlusion, Age Macular Degeneration
- Trial name
- NCT07550777
- Testing
- blood test
- Where
- Turkey (Türkiye)
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Ataturk University